Loading...
Market
What will Neuralink's next step be after CAN-PRIME trial completion by mid-2026?
2
Resolution / Starting Odds
Launch broader clinical trials • 25%
Seek commercial approval • 25%
Modify or redesign the N1 Implant • 25%
No significant action • 25%
Neuralink's announcements or strategic plans
Story
Neuralink Secures Health Canada Approval for CAN-PRIME Trial at Toronto Western Hospital to Test N1 Implant on Six Paralysis Patients
Nov 25, 2024, 06:22 PM
Neuralink, the brain-computer interface company founded by Elon Musk, has received approval from Health Canada to conduct its first trial in Canada, named CAN-PRIME. The trial will recruit six participants suffering from severe paralysis due to amyotrophic lateral sclerosis (ALS) or spinal cord injuries. This study will be held at Toronto Western Hospital and aims to evaluate the safety and effectiveness of the N1 Implant, which is designed to extend brain-computer interface (BCI) control to an investigational assistive robotic arm. Neuralink's announcement emphasizes the significance of this trial as a crucial step towards restoring both digital and physical autonomy for individuals with paralysis.
View original story
Similar markets
New regulatory approval • 25%
New patient milestone • 25%
Commercial availability plans • 25%
New technological breakthrough • 25%
Full success • 25%
Partial success • 25%
No success • 25%
Trial discontinued • 25%
Successful with no issues • 25%
Successful with minor issues • 25%
Unsuccessful • 25%
Trial halted • 25%
New software compatibility • 25%
New human participant • 25%
FDA approval • 25%
Other • 25%
Significant improvement in mobility • 25%
Moderate improvement in mobility • 25%
No improvement in mobility • 25%
Trial inconclusive • 25%
Successful with significant findings • 25%
Successful with limited findings • 25%
Unsuccessful • 25%
Indeterminate • 25%
Yes • 50%
No • 50%
Recruitment completion • 25%
Initial results published • 25%
Trial expansion approved • 25%
Trial discontinued • 25%
